-

The Law Offices of Frank R. Cruz Announces Investigation of Nutanix, Inc. (NTNX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Nutanix, Inc. (“Nutanix” or the “Company”) (NASDAQ: NTNX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On March 6, 2023, after the market closed, Nutanix disclosed that it will be unable to file its Quarterly Report on Form 10-Q for the quarter ended January 31, 2023 on time because the Company’s Audit Committee is conducting an investigation with the assistance of outside counsel. The investigation relates to “certain evaluation software from one of the Company’s third-party providers [that] was instead used for interoperability testing, validation and customer proofs of concept over a multi-year period.” The Company further disclosed that the issue is likely to result in “additional costs . . . incurred to address the additional use of the software.”

On this news, Nutanix’s stock price fell $2.27, or 7.8%, to close at $26.50 per share on March 7, 2023, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Nutanix securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

The Law Offices of Frank R. Cruz

NASDAQ:NTNX

Release Versions

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

More News From The Law Offices of Frank R. Cruz

Lost Money on Dave, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 21.25% Stock Decline

LOS ANGELES--(BUSINESS WIRE)--Dave, Inc. ("Dave" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Dave, Inc. (NASDAQ: DAVE), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Dave, Inc. on November 4, 2026.If you lost money on Dave, Inc. securities, share you...

Lost Money on MNTN, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 53.62% Stock Decline

LOS ANGELES--(BUSINESS WIRE)--MNTN, Inc. ("MNTN" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in MNTN, Inc. (NYSE: MNTN), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about MNTN, Inc. on November 4, 2026.If you lost money on MNTN, Inc. securities, share your...

Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 8.1% Stock Decline

LOS ANGELES--(BUSINESS WIRE)--Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Madrigal Pharmaceuticals, Inc. on Novem...
Back to Newsroom